NASDAQ$ERAS
Erasca Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Erasca reported its first quarter 2025 business updates and financial results, highlighting early entry of its RAS-targeting franchise into the clinic and an extended cash runway.
Erasca reported a net loss of $30.966 million for Q1 2025, with R&D expenses of $25.969 million and G&A expenses of $9.661 million. The company's cash, cash equivalents, and marketable securities stood at $411.077 million, with a projected cash runway extended to H2 2028.
- Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are expected in 2026.
- The company's cash, cash equivalents, and marketable securities totaled $411.077 million as of March 31, 2025, extending the cash runway guidance to H2 2028.
- IND clearance was received for ERAS-0015, and an IND application was submitted for ERAS-4001, advancing the RAS-targeting franchise into clinical trials.
- Preclinical data for the RAS-targeting franchise were presented at AACR 2025, reinforcing potential best-in-class profiles and new approaches to block the RAS/MAPK pathway.
Headline financials
Revenue & EPS history
Erasca · Revenue · Quarterly
$0
Forward guidance
Erasca expects its cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2028, driven by a strategic focus on its RAS-targeting franchise and potential partnership opportunities for naporafenib.
Tailwinds
- Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 are expected in 2026.
- Cash runway guidance extended to H2 2028, providing over three years of projected runway.
- Both ERAS-0015 and ERAS-4001 have demonstrated differentiated therapeutic potential in multiple preclinical models.
- The company is well-positioned to execute its mission of delivering new targeted therapies against RAS/MAPK-driven cancers.
- Strategic decision to evaluate partnership opportunities for naporafenib contributes to extended cash runway.
Headwinds
- Actual results may differ from forward-looking statements due to inherent business risks.
- Preclinical and early clinical trial results may not be predictive of future outcomes.
- Assumptions around program success probabilities may not be accurate, potentially leading to misallocation of resources.
- Potential delays in clinical trial commencement, enrollment, data readout, and completion, including IND clearance for BOREALIS-1, could occur.
- Unexpected adverse side effects or inadequate efficacy of product candidates may limit their development or commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2025
+1.1%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.3%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+11.0%
Q3 2022
Best reaction
-10.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | +1.0% | +32.1% | |
| Q4 2025 | -4.3% | -7.8% | +16.1% | |
| Q3 2025 | -4.2% | +7.9% | +35.8% | |
| Q1 2025 | -4.0% | -5.8% | +9.3% | |
| Q4 2024 | +6.0% | -8.2% | +25.0% | |
| Q3 2024 | -8.4% | -14.1% | -15.4% | |
| Q2 2024 | +8.3% | +16.7% | +27.9% | |
| Q1 2024 | -10.1% | -12.8% | +8.9% | |
| Q4 2023 | +4.0% | +9.1% | -4.5% | |
| Q3 2023 | -8.6% | -1.8% | -15.0% | |
| Q2 2023 | +10.6% | -3.2% | -0.8% | |
| Q1 2023 | -1.0% | -3.8% | -5.6% | |
| Q4 2022 | -2.7% | -5.8% | -3.8% | |
| Q3 2022 | +11.0% | +20.7% | -19.1% | |
| Q2 2022 | +2.5% | +4.4% | -10.8% | |
| Q1 2022 | +2.8% | +9.4% | -4.6% | |
| Q4 2021 | +9.1% | +8.1% | -9.7% | |
| Q3 2021 | +2.2% | -3.1% | -28.9% | |
| Q2 2021 | +4.8% | +8.9% | -12.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro